Adhering too strictly to biomedical thinking about diagnosis can prevent clinicians from empathically engaging with patients and helping them navigate their illness experiences.
AMA J Ethics. 2021;23(7):E537-541. doi:
10.1001/amajethics.2021.537.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
When a patient requests an unfamiliar treatment, the physician should not hesitate to research it before giving a categorical reply about its safety or efficacy.
Physicians should ensure that overwhelmed young patients receive the psychological support they need, especially when recommending optional treatments following the grueling main treatment for breast cancer.
Physicians should ensure that overwhelmed young patients receive the psychological support they need, especially when recommending optional treatments following the grueling main treatment for breast cancer.